KriSan Biotech Co., Ltd.

Altevogt et al. reveals how platform approaches are revolutionizing oligonucleotide manufacturing. Key advantages of platform strategy include: accelerated process development, streamlined validation, faster regulatory submissions, enhanced cost-effectiveness, and improved scalability.   At KSB, we're already implementing these advanced platform strategies. Our integrated approach delivers faster development timelines, robust process validation, comprehensive regulatory support, and seamless scale-up to commercial production, providing our clients with reduced time-to-market, lower development costs, enhanced process reliability, and greater manufacturing flexibility   Feel free to reach out to KSB at https://lnkd.in/gMxW4iME, our team of exports is capable of supporting diverse therapeutic programs from concept to commercialization.   Article link: https://lnkd.in/gbyhfFA4 #DrugDevelopment #CDMO #Biotechnology #oligonucleotide

The review article "Exploring the Next Generation of Antibody-Drug Conjugates" explores how next generation ADCs are transforming cancer therapy. According to Tsuchikama et al. the design of ADCs has evolved significantly. Key advancements include: Bispecific ADCs: These novel ADCs simultaneously target two different antigens, enhancing specificity and overcoming tumor heterogeneity. Probody–Drug Conjugates: Probody ADCs remain inactive until they reach the tumor microenvironment, minimizing off-target effects and improving safety. Immune-Stimulating ADCs: These ADCs not only kill cancer cells but also activate the immune system, potentially enhancing the overall antitumor response. Protein-degrader ADCs: These entities are the combination of two modalities: proteolysis targeting chimera (PROTAC) and monoclonal antibodies. Dual-Drug ADCs: Combining two distinct payloads in a single ADC allows for synergistic effects and better therapeutic outcomes. With over two decades of experience in conjugated drug development, KriSan offers comprehensive CDMO services from complex small molecules to cutting-edge ADC platforms, we’re committed to exceptional customer service. Our PIC/S GMP-certified facility ensures global quality standards, approved by more than 50 clients worldwide with over 100 molecules supplied. Contact KriSan to learn how we can support your project! Article link: https://lnkd.in/dGCM_Sv2 #ADC #CDMO #DrugDevelopment #PrecisionMedicine

A new report from Insight Analytics predicts the antisense oligonucleotide therapeutics market is expected to reach $64.64 billion by 2030. The growth is driven by technological breakthroughs and growing need for cutting-edge treatments for genetic and neurological disorders. The market is expected to grow at a CAGR of 13.71% from 2022 to 2030. The development of second- and third-generation antisense oligonucleotides opens doors to more effective and accessible treatments. COVID-19 pandemic has shown how RNA-based therapies, including antisense oligonucleotides, can develop treatments for new viral threats. Oligonucleotides also offer future opportunities for CDMO firms like KSB. As the demand for antisense oligonucleotide therapeutics grows, so does the need for specialized CDMO services that can facilitate the development and manufacturing of these complex molecules. KSB provides state-of-the-art CDMO services capable of supporting the entire lifecycle of drug development, from initial research to commercial manufacturing. Our know-how in the development and production of oligonucleotides places us at the right spot to help our partners bring innovative therapies to market efficiently and effectively. Article link: https://lnkd.in/g92Vsk44 #Biotech #Oligonucleotides #CDMO #MarketResearch

Antibody-drug conjugates (ADCs) have come a long way since their inception in the 1980s. Now they are at the forefront of targeted cancer therapy, with 13 FDA-approved treatments and over 200 candidates in clinical trials. Ma et al. explore the development and clinical applications of ADCs in the article "Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development." According to the authors, the global ADC market is projected to reach $20 billion by 2030, growing at an impressive 11% CAGR. Key innovations driving this growth: Bispecific ADCs pH-responsive ADCs Target-degrading ADCs Immunostimulating ADCs The advancements of ADCs are transforming patient outcomes. The collaboration between academia and industry is pushing boundaries we once thought impossible. Further, ADCs are expanding beyond oncology. We're seeing potential applications in treating other diseases, opening up entirely new markets and therapeutic possibilities. If you are working on ADC development, reach out to KSB to explore how our expertise in complex small molecules and drug conjugation technologies can accelerate your projects. Article link: https://lnkd.in/gDYqdq8v #ADCinnovation #BiotechBreakthrough #DrugDevelopment #CDMO

Antibody-drug conjugates (ADCs) combine the targeting ability of antibodies with the potent cell-killing abilities of cytotoxic drugs. In the article, "Precision targeting in oncology: The future of conjugated drugs," Li et al. explores into the future of conjugated drugs, explaining some of the mechanisms on how ADCs kill cancer cells: - Direct Cytotoxicity: Delivering the cytotoxic drug directly to the cancer cell to cause cell death. - Bystander Effect: Diffusing the drug into neighboring cancer cells to enhance the therapeutic effect. - Antibody-Dependent Cellular Cytotoxicity (ADCC): Recruiting the immune cells to kill the cancer cell. - Antibody-Dependent Cellular Phagocytosis (ADCP): Recruiting immune cells to engulf and digest the cancer cell. - Complement-Dependent Cytotoxicity (CDC): The antibody activates the complement system, leading to cancer cell lysis. With over 20 years of experience in ADC development and manufacturing, we are capable of harnessing these cutting-edge technologies. By integrating precision targeting into our CDMO services, we can offer our clients unparalleled solutions, driving their projects from feasibility to commercialization with exceptional quality and efficiency. Article link: https://lnkd.in/gjhWqeuh #DrugDevelopment #PrecisionOncology #ADCs #CDMO #BiotechInnovation #KSB #Pharma #HealthcareInnovation #CancerTreatment

Exciting days at World ADC San Diego 2024! We're here live, connecting with global ADC experts, exchanging insights, and discovering the latest advancements in antibody-drug conjugate technology. At Krisan Biotech, we're committed to becoming a preferred partner in accelerating ADC development. Meet our CEO Jamie Hung (Shu-Mei Hung) and explore how our expertise can support your ADC journey—let's shape the future of targeted therapies together! Looking forward to connecting with more industry leaders and innovators here at World ADC. Don't miss this opportunity to collaborate! #WorldADCSanDiego2024 #ADC #KrisanBiotech #Partnerships

Just 3 days to go until the World ADC San Diego 2024 Conference! We're thrilled to invite you to connect with us and explore potential collaboration opportunities. Krisan Biotech is pushing the boundaries of ADC development, and we'd love to discuss how we can work together to drive meaningful advancements in this field of targeted therapies. Gain valuable insights into Krisan Biotech's ADC CrDMO services and explore tailored partnership opportunities with our CEO at the 2024 World ADC Conference. This is a unique chance to discuss how we can drive forward ADC innovation together!. 📅 Reach out to schedule a meeting and unlock new possibilities together! #WorldADCSanDiego2024 #KrisanBiotech #ADC #CrDMO #Innovation

AusBiotech 2024 Day 3 The three-day event has come to a fruitful conclusion, and we are thrilled with the outcomes from AusBiotech 2024! This exhibition provided us with the opportunity to showcase KriSan Biotech’s CDMO services, establish new connections with partners, and explore potential collaborations. We look forward to transforming these valuable exchanges into future partnerships, driving innovation and achieving mutual success together! Thank you to everyone for your support and participation. We look forward to future collaborations!

It’s the last day of AusBiotech 2024! Don’t miss the chance to connect with us at the Taiwan Pavilion (Booth no. 66-69) and discover how our CDMO services can elevate your projects. We are here to provide total solution to your project starting from early R&D stage through clinical trials all the way to commercial production. Let’s make the most of this final day – we look forward to connecting with you! #ADC #linkerpayload #totalsolution #bestpartner

1st Day at AusBiotech! We had a fantastic first day at AusBiotech, connecting with both new and familiar faces. We engaged in promising conversations that highlighted potential collaboration opportunities for the future. It's been a rewarding experience so far, and we look forward to building on these connections in the coming days. #CrDMO #AusBiotech2024 #ADC #PDC #XDCPayloadLinker #HPAPI